Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Neoadjuvant Nivolumab for NSCLC
Randomized, open-label, phase 3 trial [CheckMate 816] Resectable stage IB to IIIA NSCLC Nivolumab+chemotherapy (n=179) vs chemotherapy (n=179) for 3 cycles followed by surgery
New Protocol: Perioperative Durvalumab with FLOT in Gastric Cancer
Phase 3, multinational, double-blind, randomized trial [MATTERHORN] Resectable gastric or gastroesophageal junction adenocarcinoma Durvalumab (n=474) vs Placebo (n=474) every 4 wee
New Reference: MRD-Guided CLL Treatment
Phase 3, multicenter, open-label trial [FLAIR ISRCTN01844152] Previously untreated chronic lymphocytic leukemia (CLL) patients Ibrutinib-venetoclax vs. Ibrutinib alone vs. Fludarab
New Indication: Bevacizumab and Erlotinib for Papillary Renal Cell Carcinoma
Open-label, phase 2 study [NCT01130519] Advanced HLRCC-associated or sporadic papillary renal-cell carcinoma Bevacizumab (10 mg/kg every 2 wks) + Erlotinib (150 mg daily)
New Reference: Maintenance Atezolizumab for Stage IB-IIIA NSCLC
Open-label, randomized, phase 3 trial (IMpower010) Completely resected stage IB-IIIA NSCLC after adjuvant platinum-based chemotherapy Atezolizumab (1,200 mg q3w for 16 cycles) vs.
New Protocol: Maintenance Sacituzumab Govitecan with Avelumab for Urothelial Carcinoma
Phase 2, randomized, open-label trial (JAVELIN Bladder Medley) Locally advanced or metastatic urothelial carcinoma without progression after first-line platinum-based chemotherapy
New Indication: Daratumumab for High-Risk Smoldering Myeloma
Phase 3, open-label, multicenter, randomized trial (AQUILA) Patients with high-risk smoldering multiple myeloma without end-organ damage Daratumumab subcutaneous monotherapy vs. ac
New Reference: Encorafenib, Cetuximab with FOLFOX for bRAF Mutated Metastatic Colorectal Cancer
Open-label, randomized, phase 3 trial (BREAKWATER) Untreated BRAF V600E–mutated metastatic colorectal cancer Encorafenib + cetuximab + mFOLFOX6 vs. investigator’s choice of che
New Reference: Enfortumab Vedotin + Pembrolizumab for Advanced Urothelial Carcinoma
Phase 3, global, open-label randomized trial (EV-302/KEYNOTE-A39) Untreated locally advanced or metastatic urothelial carcinoma (cisplatin-eligible or ineligible) Enfortumab vedoti
